Further studies are needed to determine whether tumor cell GR expression and associated GR gene expression activity correlate with response and also, to determine a measure for GR transcriptional activity that can predict the likelihood of benefit from treatment with GR antagonism in an individual patient. This evidence concerns the gene NR3C1 and neoplasm.